文献速递神经肿瘤功能神经外科

氯巴占辅助治疗脑肿瘤相关癫痫的疗效

Efficacy of clobazam as add-on therapy in brain tumor-related epilepsy.
PubMed 文献 · J Neurooncol · 2021-01-04

本研究回顾性分析了2016年4月至2019年期间在神经肿瘤跨学科门诊就诊的、经组织学确诊的原发性脑肿瘤患者,识别出35例接受氯巴占治疗的脑肿瘤相关癫痫患者。结论认为氯巴占是脑肿瘤相关癫痫的有效辅助抗癫痫药物,且可能减少合并用药。

要点

  • 氯巴占辅助治疗脑肿瘤相关癫痫,93.9%患者显示应答。
  • 30.3%患者在起始6个月内达到无癫痫发作。
  • 加用氯巴占可能允许减少或停用合并抗癫痫药物。

核心结论

  • 氯巴占作为辅助抗癫痫药物对脑肿瘤相关癫痫有效,94%的患者在6个月内显示显著应答。
  • 加用氯巴占可能减少多药治疗,因为合并抗癫痫药物可以减量并可能停用。

研究设计与样本

  • 回顾性观察性研究,纳入2016年4月至2019年神经肿瘤跨学科门诊中经组织学确诊的原发性脑肿瘤患者,识别使用氯巴占者。
  • 共35例脑肿瘤相关癫痫患者使用氯巴占,其中2例因副作用无法耐受。

主要发现

  • 33例可评估患者中,31例(93.9%)为应答者(癫痫发作频率减少>50%)。
  • 癫痫发作减少使部分患者得以调整合并抗癫痫药物。

关键数值与推荐

  • 应答定义为癫痫发作频率减少>50%。
  • 35例中2例因副作用无法耐受氯巴占。

临床怎么用

  • 对于尽管使用当前抗癫痫药物仍持续发作的原发性脑肿瘤患者,可考虑加用氯巴占。
  • 加用氯巴占后可能有机会减少合并抗癫痫药物,简化治疗方案。

局限性

  • 回顾性研究设计,样本量较小(35例)。
  • 单中心观察性研究,证据有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Brain tumor-related epilepsy (TRE) is often resistant to currently available antiepileptic medications (AEDs). Clobazam was initially approved as adjunctive AED for patients with Lennox Gastaut syndrome but has been used in TRE, despite limited evidence in this context. This observational study aims to examine the effect of clobazam on seizure frequency on patients who have a primary CNS tumor and continued seizures despite their current AEDs. METHODS: A retrospective review of patients with histologically-confirmed primary brain tumors seen in the neuro-oncology interdisciplinary clinic from April 2016-2019 was completed, and patients on clobazam were identified. Response to clobazam was defined as a greater than 50% reduction in seizure frequency. Additional data including patient and tumor characteristics, treatment course, tolerability, AEDs used prior to addition of clobazam, and AEDs concomitantly used with clobazam were collected. RESULTS: A total of 35 patients with TRE on clobazam were identified, with 2 patients unable to tolerate the medication due to side effects. Of the 33 remaining patients, a total of 31 (93.9%) of patients were deemed responders. Ten patients (30.3%) were seizure free within 6 months of clobazam initiation and 21 (63.6%) reported a significant reduction in seizure frequency. This reduction also allowed several patients to modify concurrent AEDs. CONCLUSIONS: Clobazam is an effective agent to use as add-on AED in TRE, with 94% of patients showing a significant response within 6 months. Furthermore, the addition of clobazam may yield a reduction in polypharmacy, as concomitant AEDs can be reduced and potentially withdrawn.

来源:J Neurooncol,查看原文。版权归原作者所有。

引用

  1. Brahmbhatt N, Stupp R, Bushara O, et al. Efficacy of clobazam as add-on therapy in brain tumor-related epilepsy. J Neurooncol. 2021. PMID: 33398534. doi:10.1007/s11060-020-03664-9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。